Home/Pipeline/Lou Gehrig’s disease

Lou Gehrig’s disease

Amyotrophic Lateral Sclerosis (ALS)

DiscoveryActive

Key Facts

Indication

Amyotrophic Lateral Sclerosis (ALS)

Phase

Discovery

Status

Active

Company

Genclis

About Genclis

Genclis is a biotechnology company pioneering a novel drug discovery and development platform based on Transcription Infidelity (TI), a biological mechanism that generates immunologically active variant proteins from mRNA. Its pipeline includes programs in veterinary and human allergies, severe COVID-19, Type 1 Diabetes, and Lou Gehrig's disease (ALS), with its veterinary allergy candidate appearing most advanced. The company is privately held, led by co-founder and CEO Bernard Bihain, and operates with a cautious, capital-efficient business model focused on robust preclinical de-risking before clinical advancement.

View full company profile

Therapeutic Areas

Allergy Infectious Disease Autoimmune Disease Neurodegenerative Disease

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

Drug	Company	Phase	Status
NPT520-34	Neuropore Therapies	Pre-clinical/Phase 1	Partnered (Biogen), Active
NUZ-001	Neurizon Therapeutics	Phase 2/3 (Platform Trial)	Active
CNM-Au8	Clene	Phase 2/3	Active
Masitinib	AB Science	Phase 3	Active
Undisclosed Program	Zhimeng Biopharma	Clinical	Active
SLS-005	Seelos Therapeutics	Platform Trial	Active (HEALEY ALS Platform Trial – Regimen E)
PMN442	ProMIS Neurosciences	Preclinical	Active
nAV-101	nVector	Pre-clinical	Active
ALTA-808	Alteron Therapeutics	Preclinical	IND-enabling studies launching
GM6	Genervon Biopharmaceuticals	Phase 2	Active
Treg-directed therapy for ALS	Iltoo Pharma	Pre-clinical	Active
NG CELL	NeuroGenesis Bio	Phase 2	Active